Trials / Unknown
UnknownNCT03801798
A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
A Double-blind, Randomized, Placebo Controlled, Parallel-group, Phase 2a Study to Evaluate the Efficacy and Safety of GC1102 in Combination With Nucleos(t)Ide Analogues (NAs) in Patients With Chronic Hepatitis B
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of GC1102 in combination of Nucleo(t)ide analogues (NAs) in patients with chronic hepatitis B
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GC1102 | NAs antivirals+GC1102 180,000 IU |
| OTHER | GC1102 Placebo | NAs antivirals+GC1102 Placebo |
Timeline
- Start date
- 2019-02-11
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2019-01-14
- Last updated
- 2019-12-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03801798. Inclusion in this directory is not an endorsement.